OBSV / ObsEva's (OBSV) Yselty Gets EU Nod to Treat Uterine Fibroids

ObsEva (NASDAQ: OBSV ) stock is taking off on Friday as investors react to insider buying at the clinical-stage biopharmaceutical company. Ernest Loum more_horizontal

ObsEva (NASDAQ: OBSV ) stock is bouncing back on Monday after the company's stock underwent a major dip during the prior day of trading. That crash sa more_horizontal

ObsEva (NASDAQ: OBSV ) is trending on social media, and OBSV stock is tumbling 36% to 10.85 cents. The Swiss biopharmaceutical company announced that more_horizontal

ObsEva SA (OBSV) delivered earnings and revenue surprises of 7.14% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold c more_horizontal

ObsEva SA (OBSV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the more_horizontal

Biopharmaceutical company ObsEva (NASDAQ: OBSV ) is trending today, but not necessarily in a good way. The company issued a corporate update press rel more_horizontal

ObsEva's (OBSV) Yselty receives its first marketing approval in the European Union for the treatment of uterine fibroids in adult women. Shares were u more_horizontal

GENEVA, Switzerland – May 1 2 , 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel thera more_horizontal